

Matrix Metalloproteinase 7 in Rheumatoid Arthritis Patients with Interstitial Lung Disease

Thesis

*Submitted for Partial Fulfillment of Master Degree
in internal Medicine*

By

Hana Muhammed Abdulsalam

M.B.B.Ch.,

Faculty of Medicine – Ain Shams University

Under Supervision of

Prof. Dr. Howaida Elsayed Mansour

Professor of Internal Medicine & Rheumatology

Faculty of Medicine - Ain-Shams University

Dr. Sherin Mohamed Hosny

Assistant Professor of Internal Medicine & Rheumatology

Faculty of Medicine - Ain Shams University

Dr. Nermeen Samy Khalel

Lecturer of Internal Medicine & Rheumatology

Faculty of Medicine- Ain Shams University

**Faculty of Medicine
Ain Shams University
2018**



Acknowledgement

*First of all, thanks to **Allah** to whom I relate any success in achieving any work in my life.*

*I would like to express my deepest gratitude and appreciation to **Prof. Dr. Howaida Elsayed Mansour**, Professor of Internal Medicine & Rheumatology, Ain Shams University for her sincere guidance, valuable advice and constructive remarks that added a lot to this work.*

*I offer my warmest thanks to **Dr. Sherin Mohamed Hosny**, Assistant Professor of Internal Medicine & Rheumatology, Ain Shams University for her careful supervision, kind guidance and great help.*

*I am greatly indebted to **Dr. Nermeen Samy Khalef**, Lecturer of Internal Medicine & Rheumatology, Ain Shams University, who in addition to her valuable guidance, has provided me with a great deal of support, encouragement and knowledge.*

*For my family, no word can express my feelings towards them, they are doing a lot for me. My particular appreciation to **my Family** for their care, help and encouragement throughout this work.*

*✍ **Hana Muhammed***

List of Contents

Subject	Page No.
List of Abbreviations	I
List of Tables	VI
List of Figures.....	X
Introduction.....	1
Aims of the Work.....	3
Review of Literature	
Chapter (1): Rheumatoid Arthritis	4
Chapter (2): Rheumatoid Arthritis Associated ILD	56
Chapter (3): Matrix Metalloproteinase.....	78
Patients and Methods	85
Results	96
Discussion.....	136
Summary and Conclusion	150
Recommendations	155
References	156
Arabic Summary	—

List of Abbreviations

Abb.	Full term
AASLD	American Association for the Study of Liver Diseases
ACPAs	Anti-cyclic citrullinated peptide antibodies
ACR	American College of Rheumatology
ADAM-17(TACE)	A Disintegrin and Metalloprotease 17
AIP	Acute interstitial pneumonia
Anti-CarP	Antibodies against carbamylated proteins
Anti-MCV	Antibodies against mutated citrullinated vimentin
APCS	Antigen-presenting cells
BAL	Bronchoalveolar lavage
CCP	Cyclic citrullinated peptide
CDAI	Clinical disease activity index
CMC	Carpometacarpal joint
COP	Cryptogenic organizing pneumonia
COPD	Chronic obstructive pulmonary disease
COX-2	Cyclooxygenase-2
CPFE	Combined pulmonary fibrosis and emphesyma
CPK	Creatine phosphokinase
CPPD	Calcium pyrophosphate dehydrate
CRP	C-reactive protein
CT	Computed tomography
CTD	Connective tissue disease
CTS	Carpal tunnel syndrome
CZP	Certolizumab

Abb.	Full term
DAP	Diffuse alveolar damage
DAS	Disease activity score
DAS28	DAS based on 28 joint counts
DC	Dendritic cell
DIP	Distal interphalangeal
DIP	Desquamative interstitial pneumonia
DLCO	Diffusion lung capacity of carbon monoxide
DMARDs	Disease-modifying antirheumatic drugs
EAM	Extra-articular manifestations
ECM	Extracellular matrix
EDTA	Ethylene diamine tetra-acetic acid
ESR	Erythrocyte sedimentation rate
EULAR	European League against Rheumatism
FDA	Food drug association
fl	Femtoliter
FLSs	Fibroblast-like synoviocytes
FVC	Forced vital capacity
GERD	Gastroesophageal reflux disease
GH	General health
GI	Gastrointestinal
GRADE	Grading recommendations assessment, development and evaluation
HAQ	Health assessment questionnaire
HBV	Hepatitis B virus
HCQ	Hydroxychloroquine
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
HLA	Human leucocyte antigen

Abb.	Full term
HLADRB	Human leucocyte antigen determinant region B
HRCT	High-resolution computed tomography
IFN-α	Interferon-alpha
Ig	Immunoglobulin
IIP	Idiopathic interstitial pneumonia
IL	Interleukin
IL-6R	Interleukin 6 receptor
ILD	Interstitial lung disease
IP	Interphalangeal
IPF	Idiopathic pulmonary fibrosis
JAK	Janus kinase
LEF	Leflunomide
LIP	Lymphocytic interstitial pneumonia
LT	Leukotriens
MBDA	Multi biomarker disease activity
MCP	Metacarpophalangeal
MMP	Matrix metalloproteinase
MRI	Magnetic resonance image
MR-pred	Modified-release prednisone
MT1	Membrane type 1
MTP	Metatarsophalangeal
MTX	Methotrexate
NSAIDs	Non steroidal anti-inflammatory drugs
NSIP	Non specific interstitial pneumonia
OA	Osteoarthritis
OP	Organizing pneumonia
PAD	Peptidyl arginine deaminase

Abb.	Full term
PAS	Protein activity scale
PDGF	Platelet derived growth factor
PFTs	Pulmonary function tests
PG	Prostaglandins
PIP	Proximal interphalangeal
PMN	Polymorph-nuclear
PUMP	Pump 1 metalloproteinase
RA	Rheumatoid arthritis
RAFLS	Rheumatoid arthritis fibroblast-like synoviocytes
RA-ILD	Rheumatoid arthritis associated interstitial lung disease
RA-IP	Rheumatoid arthritis idiopathic pneumonia
RASF	Rheumatoid arthritis synovial fibroblast
RF	Rheumatoid factor
RTX	Rituximab
SDAI	Simplified disease activity index
SFs	Synovial fibroblasts
SJC	Swollen joint count
SLE	Systemic lupus erythematosus
SP	Surfactant protein
SSc	Systemic sclerosis
SSZ	Sulphasalazine
TB	Tuberculosis
TCZ	Tocilizumab
TGF-β	Transforming growth factor-beta
TIMP	Tissue inhibitor metalloproteinase
TJC	Tender joint count

Abb.	Full term
TKI	Tyrosine kinase inhibitor
TLC	Total lung capacity
TMJ	Temporomandibular joint
TNF	Tumor necrosis factor
TNF-α	Tumor necrosis factor alpha
TNFAIP3	Tumour necrosis factor alpha-induced protein 3
TNFi-IR	TNFi inadequate response
UIP	Usual interstitial pneumonia
US	Ultrasound

List of Tables

Table	Title	Page
	Tables of Review	
1	The 2010 EULAR/ACR classification criteria for RA	22
2	Three of the principals of quantitative measures used to evaluate activity and severity of RA and the predefined threshold for remission, moderate, and high disease activity	31
3	Definition of remission of RA	32
4	TNF- α inhibitors agent	40
5	Non-TNFI Biologics	41
6	Summary of 2015 American College of Rheumatology recommendations for the treatment of early rheumatoid arthritis	45
7	Summary of 2015 American College of Rheumatology (ACR) recommendations for the treatment of Established rheumatoid arthritis	47
8	Summary of 2015 American College of Rheumatology recommendations for high-risk patients with established rheumatoid arthritis with moderate or high disease activity and congestive heart failure (CHF), hepatitis B or C, past history of malignancy, or serious infection(s)	49
9	Types of pulmonary involvement in RA	57
10	The four major histopathological and high-resolution computed tomography patterns of RA-ILD	62

Table	Title	Page
11	DAS 28 score interpretation	87
12	Sharp/van der Heijde or SvH scoring method for joint damage	90
13	Criteria of Warrick score	91
	Tables of Results	
1	The distribution of demographic data among our studied RA patients	96
2	Clinical manifestations among the studied RA patients	98
3	Clinical assessment of joint affection among the studied 40 RA pts	99
4	Disease activity assessed by DAS 28 ESR score among the studied 40 RA pts	100
5	Drugs received among the studied 40 RA patients	101
6	Radiological joint damage assessed by sharp score among studied RA pts	102
7	Laboratory data among the 40 studied RA patients	102
8	Serum MMP7 level among the 40 studied RA patients	103
9	Pulmonary function tests and DLCO results among the 40 studied RA patients	103
10	Interpretation of PFTs and DLCO in studied RA patients	104
11	Chest X Ray findings among the 40 studied RA patients	106

Table	Title	Page
12	Chest HRCT finding in the RA patients with ILD	107
13	Patterns of interstitial abnormalities in chest HRCT in RA patients with ILD	108
14	Assessment of ILD severity by Warrick score of HRCT chest finding RA patients	109
15	The total HRCT Warrick score among the studied RA patients with ILD	110
16	Comparison between RA patients with and without ILD as regards the demographic characteristics	111
17	Comparison between RA patients (with and without ILD) as regard drug therapy	113
18	Comparison between RA patients (with and without ILD) as regards articular manifestations and disease activity assessed by (DAS28 ESR)	114
19	Comparison between RA groups (with and without ILD) as regard the grades of disease activity measured by (DAS 28 ESR) score	116
20	Comparison between both RA groups (with and without ILD) regarding some clinical manifestations	118
21	Radiological joint damage assessed by (Sharp score) among both studied RA groups (with and without ILD)	119
22	Comparison between both studied RA groups (with and without ILD) as regards laboratory data	120

Table	Title	Page
23	Comparison between RA patients with and without ILD regarding the immunological biomarkers (RF and ACPA)	122
24	Comparison between RA patients with and without ILD regarding mean serum MMP7 level	124
25	Comparison between RA patients with and without ILD regarding pulmonary function tests and DLCO	125
26	Correlation between serum level of MMP7 with demographic, clinical, and laboratory data among the studied RA patients (with and without ILD)	127
27	Relation between SMMP7 and pulmonary manifestations in the studied RA patients with ILD (Independent-t test)	130
28	Correlation between serum MMP-7 and PFTs with DLCO among the studied RA patients	132
29	Relation between serum MMP-7 and ILD sub types detected by HRCT	134
30	Receiver operator characteristic curve (ROC) of S.MMP-7 as a laboratory predictor for RA- associated IILD	135

List of Figures

Figure	Title	Page
	Figures of Review	
1	Immune pathway in rheumatoid arthritis	14
2	Boutonniere deformity of ring finger, Z shaped deformity of thumb	15
3	Plain X-ray of hands of rheumatic arthritic patients	26
4	Erosions in multiple carpal bones and metacarpal heads detected by MRI	28
5	Mechanism of action of methotrexate	36
6	2016 EULAR recommendation for the management of rheumatoid arthritis	48
7	Potential Mechanisms Linking RA and ILD	60
8	a) Axial and b) coronal computed tomography scans of usual interstitial pneumonia pattern in a patient with rheumatoid arthritis	65
9	Computed tomography scans of a small unilateral pleural effusion and pleural thickening in a patient with rheumatoid arthritis	66
10	Functional classification of matrix metalloproteinases	79
11	Structure of MMP-7	81
12	Gene location of MMP-7	82
	Figures of Results	
1	Gender distribution among the studied RA patients	97

Figure	Title	Page
2	Disease activity as assessed by DAS28 score among RA patients	100
3	Drugs received among the studied 40 RA patients	101
4	DLCO affection among both RA studies groups	105
5	Comparison between both groups regarding age	112
6	Comparison between both groups regarding disease duration	112
7	Leflunomide intake in both studied groups	114
8	Assessment of joint affection and disease activity assessed by (DAS28 ESR) among both studied RA groups (with and without ILD)	115
9	Grades of disease activity as measured by (DAS 28 ESR) score among both studied RA groups (with and without ILD)	117
10	Radiological joint damage assessed by (Sharp score) among both studied RA groups (with and without ILD)	119
11	Comparison of some significantly different laboratory data among both studied RA groups (with and without ILD)	121
12	RF among both studied RA groups (with and without ILD)	123
13	ACPA among both studied RA groups (with and without ILD).	123
14	S.MMP7 among both studied RA groups (with and without ILD)	124

Figure	Title	Page
15	Interpretation of PFTs results among both studied RA groups (with and without ILD)	126
16	DLCO results among both studied RA groups (with and without ILD)	126
17,18	Positive correlation between serum MMP7and demographic data among the studied 40 RA patients	128
19	Positive correlation between serum MMP7and Warrick score of chest HRCT among patients with ILD	129
20	Relation between serum MMP-7 and HRCT pulmonary manifestation in RA patients with ILD	131
21,22	Correlation between serum MMP7and PFT within the studied 40 RA	133
23	Correlation between serum MMP-7 and DLCO in the 40 RA patients	133
24	Relation between serum MMP-7 and IILD sub types detected by HRCT chest	134
25	Roc curve of S.MMP7 as a laboratory predictor of ILD in RA patients	135